Showing results (111-120 of 135) with videos related to

Sort By:
Pageof 14
JHEP Reports : Innovation in Hepatology|March 20, 2023
TACE and conformal radiotherapy <i>vs</i>. TACE alone for hepatocellular carcinoma: A randomised controlled trialCyrille Féray, Loic Campion, Philippe Mathurin, et al.
The Lancet. Oncology|December 1, 2023
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trialJosep M Llovet, Masatoshi Kudo, Philippe Merle, et al.
European Journal of Gastroenterology & Hepatology|August 14, 2023
Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohortEric Nguyen-Khac, Pierre Nahon, Olivier Ganry, et al.
The New England Journal of Medicine|July 5, 2018
Cabozantinib in Patients with Advanced and Progressing Hepatocellular CarcinomaGhassan K Abou-Alfa, Tim Meyer, Ann-Lii Cheng, et al.
Biomarker Research|July 2, 2025
Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective studyBenoit You, Sebastien Couraud, Philippe Ceruse, et al.
The Lancet. Gastroenterology & Hepatology|April 8, 2019
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trialPhilippe Merle, Jean-Frederic Blanc, Jean-Marc Phelip, et al.
Lancet (London, England)|December 10, 2016
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialJordi Bruix, Shukui Qin, Philippe Merle, et al.
The Lancet. Oncology|January 23, 2019
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialAndrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, et al.
Journal of Hepatology|April 18, 2016
Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinomaGhassan K Abou-Alfa, Oscar Puig, Bruno Daniele, et al.
Transplantation|December 30, 2021
Influence of the ABO Blood Group System on Hepatocellular Carcinoma Recurrence After Liver TransplantationKayvan Mohkam, Raëf Abdallah, Gisèle N'kontchou, et al.
Pageof 14